Britain and America have finalized a significant bilateral deal that will preserve zero tariffs on UK pharmaceutical exports entering the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to boost spending on medicines through the public health system. This commitment secures that import taxes on these key products will stay at nothing for a timeframe of the next three years.
This development comes after recent warnings to dramatically increase tariffs on branded drug products, with figures mentioned as high as double the cost.
"This deal between the United Kingdom reinforces the worldwide climate for innovative medicines and establishes much-needed fairness to transatlantic medicine commerce," an announcement noted.
Commercial Impact
Medicines represent one of the UK's biggest goods shipped to the America, which is clearly the biggest destination for leading British pharmaceutical firms.
Statistics reveal that in the year to the end of September, the UK shipped drugs valued at £11.1bn to the US. This amount represented a significant portion of British export trade in that timeframe.
"This deal protects jobs, boosts funding and facilitates the UK to establish itself as a international leader for medical research," the Business and Trade Secretary remarked.
Detailed British Pledges
The pact entails several notable changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new medicines to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to raise total public funding on treatments from 0.3% of GDP to 0.6% over the coming ten years.
- Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to control costs will be limited at 15%. In the past, repayments were more than 20%.
Industry Background
This agreement takes place against a long-running row between the drug companies and the UK government over spending levels and regulatory access.
These tensions were intensified by arguments that US patients were charged a premium for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or scrapped, while substantial expansions have been directed toward US facilities.
The Science Minister stated that the NHS had to increase expenditure on medicines, noting that its spending on drugs had decreased as a proportion of its overall budget over the last ten years.
